JBIO Earnings — Jade Biosciences, Inc. Common Stock Post-ER Performance | BigEarnings
JBIO — Jade Biosciences, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$21.04
Market Cap$1.0B
P/E—
52W Range$6.57 – $28.00
Next Earnings2026-08-12
About Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
